Q-omics provides the consensus-scored HSD3B1 profile across patient tissues and cancer cell-line models. HSD3B1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, HSD3B1 is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, HSD3B1 RNA expression shows 12,246 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THCA, BLCA, and GBM as cancer lineages where HSD3B1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSD3B1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSD3B1 survival associations across molecular data types. HSD3B1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSD3B1 RNA expression–survival associations across cancer types. High HSD3B1 expression shows unfavorable associations in THCA, CHOL, SCLC, KIRC and OV, but favorable associations in BLCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for HSD3B1 RNA expression.
This table summarizes HSD3B1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HSD3B1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSD3B1 shows lower tumor expression in KIRP, KIRC, LIHC and BRCA and higher tumor expression in BLCA and UCEC. The BLCA box plot shows higher HSD3B1 RNA expression in tumor versus normal tissue (log2 FC = +0.162, t-test p = .015).
This table shows molecular features associated with HSD3B1 in patient tissues and cancer cell lines. In patient samples, HSD3B1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HSD3B1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
